Close Menu
Stratnews GlobalStratnews Global
    Facebook X (Twitter) Instagram
    Trending
    • Forget FPIs. Follow the Earnings: Sanjay Bakshi on Investing in India
    • Beyond the Strait of Hormuz: The New Battle for Energy and Trade Security
    • India’s Working-Hour Rules: Why Factories Struggle to Scale
    • Vietnam vs India: What Must Change for India to Grow at 10%?
    • India’s Green Transition: Can Sustainability and Competitiveness Go Together?
    • Can A Weakening Indian Rupee Become A Global Currency?
    • India’s Resilience Is Facing A Perfect Storm
    • Why Are Indian MSMEs So Resilient?
    • Support Us
    Stratnews GlobalStratnews Global
    Write for Us
    Thursday, November 19
    • Space
    • Science
    • AI and Robotics
    • Industry News
    • Support Us
    Stratnews GlobalStratnews Global
    Home » Novo Nordisk’s CagriSema Helps Diabetic Patients Lose 15.7% Weight in Trial

    Novo Nordisk’s CagriSema Helps Diabetic Patients Lose 15.7% Weight in Trial

    Arushi PandeyBy Arushi PandeyMarch 10, 2025 Science No Comments2 Mins Read
    Novo Nordisk’s CagriSema

    Novo Nordisk’s CagriSema Shows 15.7% Weight Loss in Type 2 Diabetes Trial

    Novo Nordisk announced on Monday that its experimental obesity drug, CagriSema, helped overweight or obese patients with type 2 diabetes lose an average of 15.7% of their body weight over 68 weeks. This latest phase III trial data is crucial for understanding the potential of Novo Nordisk’s CagriSema, especially after an earlier trial in people without diabetes showed lower-than-expected weight loss results.

    Promising Results from REDEFINE 2 Trial

    The new data comes from the REDEFINE 2 trial, which involved around 1,200 participants with type 2 diabetes and a body mass index (BMI) of 27 or higher. The trial used a flexible protocol, allowing patients to adjust their dosage throughout the study. By the end of the 68-week period, 61.9% of participants receiving CagriSema were on the highest dose.

    Patients treated with CagriSema achieved a 15.7% reduction in weight, compared to just 3.1% in the placebo group. Novo Nordisk highlighted that if all participants adhered fully to the treatment, the overall weight loss effect would remain at this level.

    How Novo Nordisk’s CagriSema Works

    CagriSema is a weekly injectable drug that combines two key components:

    • Semaglutide – the active ingredient in Wegovy, which mimics the gut hormone GLP-1 to regulate appetite and blood sugar levels.
    • Cagrilintide – a molecule that mimics the pancreatic hormone amylin, which helps control hunger.

    By combining these two hormones, CagriSema effectively reduces hunger while also managing blood glucose, making it a potential breakthrough treatment for patients struggling with both obesity and diabetes.

    A Key Step in Obesity and Diabetes Treatment

    The results from the REDEFINE 2 trial strengthen CagriSema’s case as a next-generation obesity drug, particularly for those with type 2 diabetes. Novo Nordisk’s findings will be closely watched as the company seeks regulatory approval and potential commercialisation of the drug.

    With inputs from Reuters

    Author

    • Arushi Pandey
      Arushi Pandey
      View all posts
    Featured
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram WhatsApp
    Arushi Pandey

      Keep Reading

      Social Media Bans Expand For Children Worldwide

      Perplexity Valuation Could Exceed $30 Billion

      Vatican Renewable Energy Plant To Power Holy See

      Terrier Cyber Quest 2026 Opens National Hackathon

      Firebase Banking Scams Prompt India Action Against Google

      China Indonesia Energy Technology Cooperation Expands

      Add A Comment
      Leave A Reply Cancel Reply

      Anti Drone System (CUAS)
      Latest Posts

      Forget FPIs. Follow the Earnings: Sanjay Bakshi on Investing in India

      November 12, 2026

      Beyond the Strait of Hormuz: The New Battle for Energy and Trade Security

      November 6, 2026

      India’s Working-Hour Rules: Why Factories Struggle to Scale

      October 29, 2026

      Vietnam vs India: What Must Change for India to Grow at 10%?

      October 22, 2026

      India’s Green Transition: Can Sustainability and Competitiveness Go Together?

      October 15, 2026

      Can A Weakening Indian Rupee Become A Global Currency?

      October 8, 2026

      India’s Resilience Is Facing A Perfect Storm

      October 1, 2026

      Why Are Indian MSMEs So Resilient?

      September 24, 2026

      9/11@25: How Terrorism Reshaped Global Geopolitics

      September 17, 2026

      The Indian Economy Keeps Beating Expectations

      September 10, 2026

      Subscribe to News

      Get the latest sports news from NewsSite about world, sports and politics.

      • Astronomical Events
      • Space Missions
      • Industry News
      • Science
      StratNewsGlobal Tech
      Facebook X (Twitter) Instagram LinkedIn YouTube
      © 2026 StratNews Global, A unit of BharatShakti Communications LLP
      • About Us
      • Contributors
      • Copyright
      • Contact
      • Write for Us

      Type above and press Enter to search. Press Esc to cancel.